Journal profile · Hematology
Hematology/Oncology Clinics of North America
ISSN 0889-8588 · eISSN 1558-1977 · W.B. Saunders Ltd · UNITED STATES · Bimonthly · Founded 1987
Hematology/Oncology Clinics of North America: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.05; subscription journal; APC about USD 3,950; review 6–12 weeks (community reports); community-reported acceptance: fairly easy; 103 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Hematology/Oncology Clinics of North America is published by W.B. Saunders Ltd and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research and Acute Myeloid Leukemia Research, together about 25.4% of its articles. Its main subfields are Hematology. (generated from OpenAlex topic counts and CAS ranking data)
Hematology/Oncology Clinics updates you on the latest trends in patient management, keeps you up to date on the newest advances, and provides a sound basis for choosing treatment options. Under the direction of an experienced guest editor, each issue focuses on a single topic in hematology and oncology, including hemostasis and thrombosis, molecular and cellular basis of hematology, coagulation disorders, and cancers—bone, gastrointestinal, head and neck, lymphomas, neuroendocrine, breast, renal cell, melanoma, and more. Hematology/Oncology Clinics of North America is published six times each year, in February, April, June, August, October, and December.
From the journal's Aims & Scope
Research area (LetPub): Hematology
Editorial board by country: none in mainland China; most named United States 4 (4 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Lymphoma Diagnosis and TreatmentMedicine10.9%
- Chronic Lymphocytic Leukemia ResearchMedicine8.1%
- Acute Myeloid Leukemia ResearchMedicine6.4%
- Hemoglobinopathies and Related DisordersMedicine5.9%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance4.5%
- Chronic Myeloid Leukemia TreatmentsMedicine4.1%
- CAR-T cell therapy researchMedicine4%
- Viral-associated cancers and disordersMedicine3.8%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Hematology | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
| Minor | Hematology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Hematology | Zone 3 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.05LetPub ·
- Impact factor (publisher)
- 2.7Publisher website ·
- CiteScore 2026-06
- 5.7LetPub ·
- CiteScore (publisher)
- 4.1Publisher website ·
- SJR 2026-06
- 1.42LetPub ·
- SNIP 2026-06
- 1.05LetPub ·
- h-index
- 74LetPub ·
- h-index
- 123OpenAlex ·
- i10-index
- 1,990OpenAlex ·
- 2-year mean citedness
- 2.51OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 2.65%LetPub ·
Volume
- Articles per year
- 68LetPub ·
Articles by year OpenAlex count · 3,811 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 55 | 9 | 36 |
| 2025 | 103 | 17 | 182 |
| 2024 | 121 | 21 | 483 |
| 2023 | 134 | 23 | 1,110 |
| 2022 | 112 | 28 | 1,229 |
| 2021 | 118 | 22 | 1,631 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,950 / EUR 3,460 / GBP 3,100 / JPY 424,490 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare1 items from the author guidelines
- Abstract
- ≤ 250 words
Article types accepted1
- reviewThe Clinics and Advances review article journals publish high-quality, invited review content on a bi-monthly, quarterly or annual basis. Each journal’s editori…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Authorship
Review articles should not have more than 4 authors; all authors should have degrees (no students). Model summary
By adhering to the authorship requirements stated above, authors meet the International Committee of Medical Journal Editors (ICMJE) criteria [updated version January 2024] on authorship.
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- Peer review
Authorship in the Clinics is by invitation only; unsolicited submissions are not accepted. Model summary
Please note that authorship in the Clinics is by invitation only. We do not accept unsolicited submissions.
Source ↗Publisher website ·- Preprints Preprints
Abstract must be concise and factual, not exceeding 250 words. Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- W.B. Saunders Ltd
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1987
- ISSN
- 0889-8588
- Electronic ISSN
- 1558-1977
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Hematology/Oncology Clinics of North America
What CAS zone is Hematology/Oncology Clinics of North America in?
In the 2025 upgraded edition of the CAS Journal Ranking, Hematology/Oncology Clinics of North America is in Zone 3 of Medicine, and in Zone 3 of the minor category Hematology / Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Hematology/Oncology Clinics of North America?
The latest impact factor listed by LetPub is 3.05; CiteScore 5.7, h-index 123.
How long does peer review take at Hematology/Oncology Clinics of North America?
Authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Hematology/Oncology Clinics of North America based?
Of the 4 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Hematology/Oncology Clinics of North America?
According to LetPub and DOAJ records, Hematology/Oncology Clinics of North America is indexed in SCIE and Scopus.
Is Hematology/Oncology Clinics of North America open access, and what is the APC?
Hematology/Oncology Clinics of North America is a subscription journal. APC about USD 3,950.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .